Revive Therapeutics Ltd. (RVVTF)
- Previous Close
0.0080 - Open
0.0075 - Bid 0.0075 x --
- Ask 0.0085 x --
- Day's Range
0.0075 - 0.0075 - 52 Week Range
0.0060 - 0.0360 - Volume
27,912 - Avg. Volume
459,522 - Market Cap (intraday)
3.139M - Beta (5Y Monthly) -0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Nov 27, 2024 - Dec 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.
revivethera.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: RVVTF
View MorePerformance Overview: RVVTF
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVVTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVVTF
View MoreValuation Measures
Market Cap
3.00M
Enterprise Value
2.46M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.67
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.52%
Return on Equity (ttm)
-62.83%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.62M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
773.07k
Total Debt/Equity (mrq)
0.35%
Levered Free Cash Flow (ttm)
-2.04M